Ardelyx, Inc. ARDX
Ardelyx, Inc. (Nasdaq: ARDX) is a GI/hepatology drug developer. Its lead program, ACCEL, is in Phase 3 for Chronic idiopathic constipation (CIC). Its next catalyst on record is ACCEL (tenapanor for CIC): Topline data (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ACCEL (tenapanor for CIC) — Topline data (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IBSRELA (tenapanor) | IBS-C | small molecule | Approved |
| XPHOZAH (tenapanor) | Hyperphosphatemia in CKD on dialysis | small molecule | Approved |
| ACCEL (tenapanor for CIC) | Chronic idiopathic constipation | small molecule | Phase 3 |
| Tenapanor pediatric trials (IBS-C) | IBS-C in pediatric patients | small molecule | Phase 1 |
| RDX10531 | Multiple therapeutic areas (unspecified) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 31, 2026completed enrollment Ardelyx completed enrollment ahead of schedule in its Phase 3 ACCEL trial of tenapanor for chronic idiopathic constipation with topline data expected in second half of 2027.
The Company has completed enrollment ahead of schedule in its Phase 3 clinical trial, ACCEL, evaluating tenapanor for the treatment of chronic idiopathic constipation (CIC) in adults.
Filing - Feb 19, 2026started Phase 3 ACCEL trial of tenapanor (IBSRELA) in chronic idiopathic constipation launched, first patient dosed in Q1 2026.
has launched a Phase 3 trial, ACCEL, to assess tenapanor in patients with CIC, dosing the first patient in Q1 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.